Articles in this month's edition of Perfusion cover several topics, but my eye was drawn to the retrospective analysis by Kindzelski and his co-workers of the association between blood transfusion and acute kidney injury (AKI) in the context of cardiac surgery. 1 The new world of online everything now allows not only publication before print, but also correspondence before print. This allows letters to provide comment on articles in the same print edition, giving readers the chance to benefit from the opinions of experts in the field. We are in precisely this position today, with comments from Professor Xue's department in Beijing adding food for thought on the work by Kindzelski et al. 2 This is a definite advance over the past. (Less of an advance is the example contained in the main article of the use of the word 'emergent' -meaning 'rising out of a surrounding medium', but commonly used metaphorically -for 'emergency'. Why has it become popular? Surely not simply because it rhymes with 'urgent' -will I have to put up with 'elergent' for 'elective' next?)
Putting this irritable pedantry aside, the article is fascinating reading. After collecting data from almost 1200 patients, they have been able to show a clear link between the transfusion of red cells or fresh frozen plasma (FFP) and AKI, with cryoprecipitate and platelets having no clinically significant association. The reader is tempted to draw conclusions which the authors, themselves, have been careful to avoid, i.e., transfusion is a direct cause of AKI. The temptation arises because the association is strong and there is a plausible mechanism: the greater fragility of transfused red cells leads to increased haemolysis with overloading of the body's iron-binding capacity, resulting in free haemoglobin and iron, both of which are nephrotoxic. This issue of Perfusion also publishes a review that points out that the more rigid transfused red cells also impair the microcirculation, 3 but however tempting it is to slip mentally from association to cause, we know that transfusion may simply be a surrogate marker of the real cause.
Argument from association is often boosted by the use of multivariate analysis, but, as the accompanying letter points out, if important factors are omitted, then the studied variable may appear to gain support by clinging to the coat-tails of a more important, but ignored, factor. A case can also be strengthened using propensity scores, but such comparisons are only as good as the matching and it will be difficult to match large numbers of transfused and untransfused patients -the indications for transfusion will reveal unmatchable confounding factors. There are a number of less technical ways that an association can hint at cause and effect (e.g. the strength of the association, the consistency of the association in repeat studies, a dose-effect relationship) and the link between transfusion and AKI satisfies most of these 4 so, perhaps, this is enough to make us think we shouldn't be transfusing patients.
But wait. These possible mechanisms of injury may be of little consequence because the alternative, anaemia, is also associated with adverse outcomes, including AKI, and it too has a plausible and obvious mechanism of injury. Perhaps anaemia, the trigger for transfusion, is the real cause of AKI. Observational studies have suggested it is 5 and it is a testable hypothesis. The TITRe2 trial was the largest prospective comparison of two transfusion triggers, with over 2,000 patients, 6 yet it found no difference in AKI between patients transfused when their haemoglobin reduced to 90 g.L -1 and those who were transfused only if their haemoglobin reduced to 75 g.L -1 . This negative result is in keeping with other studies included in the Cochrane Library systematic review, which included almost 4,000 additional patients. 7 It is curious that any benefit of avoiding transfusion seems to balance exactly the risk of renal injury from anaemia. In this context, at least, transfusion has not been shown to benefit patients. In fact, when Habib et al. reported the outcome of patients with the same values of minimum haemoglobin concentration during surgery, those who were transfused tended to have slightly worse renal outcomes. 8 Unfortunately, this is does not provide strong support for a restrictive transfusion practice because the study was not prospective or randomised, so it is likely that, at any given haemoglobin concentration, the patients who were spared transfusion were younger, fitter and inherently less likely to come to harm.
Perhaps the best we can say is that both anaemia and transfusion are injurious to our patients and since avoidance of one will lead to avoidance of the other, that is where our efforts should be concentrated. A UK national audit found that a haemoglobin concentration of less than 110 g.L -1 is associated with a threefold increase in mortality after cardiac surgery. 9 Therefore, if an anaemic patient can wait for their surgery, they probably should while the cause is investigated and treated. When time is more pressing, then a pre-operative transfusion may help, but a pilot study of anaemic patients randomised to transfusion of two units of red cells (or not) 24 to 48 hours before surgery failed to demonstrate any difference in outcome. 10 It is possible that the transfusion should have been earlier to separate and transfusion injury from the time of surgery, because renal injury was associated with transferrin saturation in both groups. The use of erythropoietin to treat anaemia acutely has been found to reduce transfusion requirement and even to reduce AKI, 11 but the number of patients treated has been small. Furthermore, erythropoietin has its own list of adverse effects, which may outweigh any benefit.
Mild AKI is so common that there is a tendency to be blasé about it. What harm can arise from a transient increase in serum creatinine? In fact, there is good evidence that late outcomes are worse, even in those suffering stage I injury (a modestly increased serum creatinine) 12 , even though 30-day mortality is not increased. Is that the end result of our perioperative management, including decisions on transfusion, or were these patients vulnerable in some way pre-operatively and first revealed that vulnerability by suffering an exaggerated response to a degree of injury that other patients could accommodate without consequence? If the latter, these patients would have been pre-destined to a shortened life expectancy compared to their peers regardless of surgery. One day, we may be able to identify such patients, but, for now, it obviously behoves us to treat all patients as though they are exquisitely delicate and avoid all events associated with adverse outcomes. Kindzelski et al. tell us that we should avoid transfusion and we must pay heed. We should treat anaemia at the first opportunity preoperatively, address surgical bleeding at every stage of the operation, use cell salvage, give tranexamic acid … and hope that our interventions do not have adverse effects of their own.
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